7/15/2011 9:08:45 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, announced today a publication in the journal Nature that identifies dysregulated activity of the serine pathway as a novel metabolic target in certain breast cancers. The publication also demonstrates a powerful method to identify new and important metabolic targets in cancer. Taken together, this research provides important new validation for the emerging field of cancer metabolism.
comments powered by